Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global anticoccidial drugs market was valued at $171.3 million in 2021, and is projected to reach $257.8 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Coccidiosis is one of the most common diseases in the poultry population is caused by protozoan parasites of the genus Eimeria. These are obligated intracellular parasites with complex life cycles including sexual and asexual stages. These parasites affect the intestine making it prone to other diseases (necrotic enteritis) and reducing the ability of this organ to absorb nutrients. This disease is transmitted or spread by mechanical carriers such as insects and wild birds. However, the Eimeria eggs (oocysts) can be mechanically transported by wild birds, these parasites are host-specific and thus wild birds do not serve as a biological reservoir. Hence, this disease can be controlled by the help of anticoccidial drugs. The short life cycle of a broiler eliminates Eimeria completely from the gut by using the drugs like coccidicides that kill the parasites.

The growth of the anticoccidial drugs market is driven by the increase in development of advanced anticoccidial drugs, increase in the government initiatives for the awareness about the coccidiosis and its medications. Moreover, the high demand of animal protein food such as meat, milk, and others, increase in the outsourcing of the development of the anticoccidial drugs, and the development in the pharmaceutical and biotechnology industries also helps in the growth of the market. However, a stringent government regulations that restricts the usage of anticoccidial drugs in livestock and the use of alternative medicines such as vaccines and herbal medicines to treat coccidiosis are expected to hinder the growth of this market. Conversely, the rise in awareness about the new products available at affordable rates is expected to create lucrative opportunities for the market.

The global anticoccidial drugs market is segmented based on drug class, drug action, animal type, and region. On the basis of drug class, the market is bifurcated into ionophore and synthetic drugs. On the basis of drug action, the market is classified into coccidiostatic and coccidiocidal. On the basis of animal type, the market is classified into poultry, cattle and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include Bayer AG, Boehringer Ingelheim International GmbH, Ceva sante animale, Dosh Pharmaceuticals Private Limited, Huvepharma EOOD, Merck & Co., Inc., Venkateshwara hatcheries Private Limited, Vetoquinol SA, Virbac SA, Zoetis Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anticoccidial drugs market analysis from 2021 to 2031 to identify the prevailing anticoccidial drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the anticoccidial drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global anticoccidial drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Ionophore
Synthetic Drugs

By Drug Action

Coccidiostatic
Coccidiocidal

By Animal Type

Poultry
Cattle
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

boehringer ingelheim animal health - us
Ceva sante animale
Huvepharma EOOD
Merck & Co., Inc
Venkateshwara hatcheries Private Limited
Dosh Pharmaceuticals
Vetoquinol SA
Virbac SA
Zoetis Inc
Bayer AG

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Ionophore
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Synthetic Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION
5.1 Overview
5.1.1 Market size and forecast
5.2 Coccidiostatic
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Coccidiocidal
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2 Poultry
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Cattle
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Drug Action
7.2.4 North America Market size and forecast, by Animal Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Drug Class
7.2.5.1.3 Market size and forecast, by Drug Action
7.2.5.1.4 Market size and forecast, by Animal Type
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Drug Class
7.2.5.2.3 Market size and forecast, by Drug Action
7.2.5.2.4 Market size and forecast, by Animal Type
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Drug Class
7.2.5.3.3 Market size and forecast, by Drug Action
7.2.5.3.4 Market size and forecast, by Animal Type
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Drug Action
7.3.4 Europe Market size and forecast, by Animal Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Drug Class
7.3.5.1.3 Market size and forecast, by Drug Action
7.3.5.1.4 Market size and forecast, by Animal Type
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Drug Class
7.3.5.2.3 Market size and forecast, by Drug Action
7.3.5.2.4 Market size and forecast, by Animal Type
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Drug Class
7.3.5.3.3 Market size and forecast, by Drug Action
7.3.5.3.4 Market size and forecast, by Animal Type
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Drug Class
7.3.5.4.3 Market size and forecast, by Drug Action
7.3.5.4.4 Market size and forecast, by Animal Type
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Drug Class
7.3.5.5.3 Market size and forecast, by Drug Action
7.3.5.5.4 Market size and forecast, by Animal Type
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Drug Class
7.3.5.6.3 Market size and forecast, by Drug Action
7.3.5.6.4 Market size and forecast, by Animal Type
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Drug Action
7.4.4 Asia-Pacific Market size and forecast, by Animal Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Drug Class
7.4.5.1.3 Market size and forecast, by Drug Action
7.4.5.1.4 Market size and forecast, by Animal Type
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Drug Class
7.4.5.2.3 Market size and forecast, by Drug Action
7.4.5.2.4 Market size and forecast, by Animal Type
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Drug Class
7.4.5.3.3 Market size and forecast, by Drug Action
7.4.5.3.4 Market size and forecast, by Animal Type
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Drug Class
7.4.5.4.3 Market size and forecast, by Drug Action
7.4.5.4.4 Market size and forecast, by Animal Type
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Drug Class
7.4.5.5.3 Market size and forecast, by Drug Action
7.4.5.5.4 Market size and forecast, by Animal Type
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Drug Class
7.4.5.6.3 Market size and forecast, by Drug Action
7.4.5.6.4 Market size and forecast, by Animal Type
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Drug Action
7.5.4 LAMEA Market size and forecast, by Animal Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Drug Class
7.5.5.1.3 Market size and forecast, by Drug Action
7.5.5.1.4 Market size and forecast, by Animal Type
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Drug Class
7.5.5.2.3 Market size and forecast, by Drug Action
7.5.5.2.4 Market size and forecast, by Animal Type
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Drug Class
7.5.5.3.3 Market size and forecast, by Drug Action
7.5.5.3.4 Market size and forecast, by Animal Type
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Drug Class
7.5.5.4.3 Market size and forecast, by Drug Action
7.5.5.4.4 Market size and forecast, by Animal Type
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Top player positioning, 2021
8.5. Competitive Dashboard
8.6. Competitive Heatmap
8.7. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 boehringer ingelheim animal health - us
9.1.1 Company overview
9.1.2 Key Executives
9.1.3 Company snapshot
9.1.4 Operating business segments
9.1.5 Product portfolio
9.1.6 Business performance
9.1.7 Key strategic moves and developments
9.2 Ceva sante animale
9.2.1 Company overview
9.2.2 Key Executives
9.2.3 Company snapshot
9.2.4 Operating business segments
9.2.5 Product portfolio
9.2.6 Business performance
9.2.7 Key strategic moves and developments
9.3 Huvepharma EOOD
9.3.1 Company overview
9.3.2 Key Executives
9.3.3 Company snapshot
9.3.4 Operating business segments
9.3.5 Product portfolio
9.3.6 Business performance
9.3.7 Key strategic moves and developments
9.4 Merck & Co., Inc
9.4.1 Company overview
9.4.2 Key Executives
9.4.3 Company snapshot
9.4.4 Operating business segments
9.4.5 Product portfolio
9.4.6 Business performance
9.4.7 Key strategic moves and developments
9.5 Venkateshwara hatcheries Private Limited
9.5.1 Company overview
9.5.2 Key Executives
9.5.3 Company snapshot
9.5.4 Operating business segments
9.5.5 Product portfolio
9.5.6 Business performance
9.5.7 Key strategic moves and developments
9.6 Dosh Pharmaceuticals
9.6.1 Company overview
9.6.2 Key Executives
9.6.3 Company snapshot
9.6.4 Operating business segments
9.6.5 Product portfolio
9.6.6 Business performance
9.6.7 Key strategic moves and developments
9.7 Vetoquinol SA
9.7.1 Company overview
9.7.2 Key Executives
9.7.3 Company snapshot
9.7.4 Operating business segments
9.7.5 Product portfolio
9.7.6 Business performance
9.7.7 Key strategic moves and developments
9.8 Virbac SA
9.8.1 Company overview
9.8.2 Key Executives
9.8.3 Company snapshot
9.8.4 Operating business segments
9.8.5 Product portfolio
9.8.6 Business performance
9.8.7 Key strategic moves and developments
9.9 Zoetis Inc
9.9.1 Company overview
9.9.2 Key Executives
9.9.3 Company snapshot
9.9.4 Operating business segments
9.9.5 Product portfolio
9.9.6 Business performance
9.9.7 Key strategic moves and developments
9.10 Bayer AG
9.10.1 Company overview
9.10.2 Key Executives
9.10.3 Company snapshot
9.10.4 Operating business segments
9.10.5 Product portfolio
9.10.6 Business performance
9.10.7 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 2. ANTICOCCIDIAL DRUGS MARKET FOR IONOPHORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. ANTICOCCIDIAL DRUGS MARKET FOR SYNTHETIC DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOSTATIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOCIDAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 8. ANTICOCCIDIAL DRUGS MARKET FOR POULTRY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. ANTICOCCIDIAL DRUGS MARKET FOR CATTLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. ANTICOCCIDIAL DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. ANTICOCCIDIAL DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 17. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 20. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 23. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 26. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 33. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 34. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 36. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 37. UK ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 39. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ITALY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 42. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 45. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 48. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 51. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 52. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 53. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CHINA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 58. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 59. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 62. INDIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 70. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 73. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 74. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 83. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 84. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY EXECUTIVES
TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: COMPANY SNAPSHOT
TABLE 87.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: OPERATING SEGMENTS
TABLE 88.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: PRODUCT PORTFOLIO
TABLE 89.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: NET SALES
TABLE 90.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY STRATERGIES
TABLE 92.CEVA SANTE ANIMALE: KEY EXECUTIVES
TABLE 92.CEVA SANTE ANIMALE: COMPANY SNAPSHOT
TABLE 93.CEVA SANTE ANIMALE: OPERATING SEGMENTS
TABLE 94.CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
TABLE 95.CEVA SANTE ANIMALE: NET SALES
TABLE 96.CEVA SANTE ANIMALE: KEY STRATERGIES
TABLE 98.HUVEPHARMA EOOD: KEY EXECUTIVES
TABLE 98.HUVEPHARMA EOOD: COMPANY SNAPSHOT
TABLE 99.HUVEPHARMA EOOD: OPERATING SEGMENTS
TABLE 100.HUVEPHARMA EOOD: PRODUCT PORTFOLIO
TABLE 101.HUVEPHARMA EOOD: NET SALES
TABLE 102.HUVEPHARMA EOOD: KEY STRATERGIES
TABLE 104.MERCK & CO., INC: KEY EXECUTIVES
TABLE 104.MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 105.MERCK & CO., INC: OPERATING SEGMENTS
TABLE 106.MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 107.MERCK & CO., INC: NET SALES
TABLE 108.MERCK & CO., INC: KEY STRATERGIES
TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY EXECUTIVES
TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 111.VENKATESHWARA HATCHERIES PRIVATE LIMITED: OPERATING SEGMENTS
TABLE 112.VENKATESHWARA HATCHERIES PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 113.VENKATESHWARA HATCHERIES PRIVATE LIMITED: NET SALES
TABLE 114.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY STRATERGIES
TABLE 116.DOSH PHARMACEUTICALS: KEY EXECUTIVES
TABLE 116.DOSH PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 117.DOSH PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 118.DOSH PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 119.DOSH PHARMACEUTICALS: NET SALES
TABLE 120.DOSH PHARMACEUTICALS: KEY STRATERGIES
TABLE 122.VETOQUINOL SA: KEY EXECUTIVES
TABLE 122.VETOQUINOL SA: COMPANY SNAPSHOT
TABLE 123.VETOQUINOL SA: OPERATING SEGMENTS
TABLE 124.VETOQUINOL SA: PRODUCT PORTFOLIO
TABLE 125.VETOQUINOL SA: NET SALES
TABLE 126.VETOQUINOL SA: KEY STRATERGIES
TABLE 128.VIRBAC SA: KEY EXECUTIVES
TABLE 128.VIRBAC SA: COMPANY SNAPSHOT
TABLE 129.VIRBAC SA: OPERATING SEGMENTS
TABLE 130.VIRBAC SA: PRODUCT PORTFOLIO
TABLE 131.VIRBAC SA: NET SALES
TABLE 132.VIRBAC SA: KEY STRATERGIES
TABLE 134.ZOETIS INC: KEY EXECUTIVES
TABLE 134.ZOETIS INC: COMPANY SNAPSHOT
TABLE 135.ZOETIS INC: OPERATING SEGMENTS
TABLE 136.ZOETIS INC: PRODUCT PORTFOLIO
TABLE 137.ZOETIS INC: NET SALES
TABLE 138.ZOETIS INC: KEY STRATERGIES
TABLE 140.BAYER AG: KEY EXECUTIVES
TABLE 140.BAYER AG: COMPANY SNAPSHOT
TABLE 141.BAYER AG: OPERATING SEGMENTS
TABLE 142.BAYER AG: PRODUCT PORTFOLIO
TABLE 143.BAYER AG: NET SALES
TABLE 144.BAYER AG: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1. SEGMENTATION OF ANTICOCCIDIAL DRUGS MARKET,2021-2031
FIGURE 2.ANTICOCCIDIAL DRUGS MARKET,2021-2031
FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
FIGURE 4.PORTER FIVE-1
FIGURE 5.PORTER FIVE-2
FIGURE 6.PORTER FIVE-3
FIGURE 7.PORTER FIVE-4
FIGURE 8.PORTER FIVE-5
FIGURE 9.ANTICOCCIDIAL DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10.ANTICOCCIDIAL DRUGS MARKET,BY DRUG CLASS,2021(%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF IONOPHORE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF SYNTHETIC DRUGS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 13.ANTICOCCIDIAL DRUGS MARKET,BY DRUG ACTION,2021(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF COCCIDIOSTATIC ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COCCIDIOCIDAL ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 16.ANTICOCCIDIAL DRUGS MARKET,BY ANIMAL TYPE,2021(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF POULTRY ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CATTLE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
FIGURE 20.ANTICOCCIDIAL DRUGS MARKET BY REGION,2021
FIGURE 21.U.S. ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 22.CANADA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 23.MEXICO ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 24.GERMANY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 25.FRANCE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 26.UK ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 27.ITALY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 28.SPAIN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 29.REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 30.JAPAN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 31.CHINA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 32.AUSTRALIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 33.INDIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 34.SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 35.REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 36.BRAZIL ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 37.SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 38.SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 39.REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44.TOP PLAYER POSITIONING, 2021
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.BOEHRINGER INGELHEIM ANIMAL HEALTH - US.: NET SALES ($MILLION)
FIGURE 48.CEVA SANTE ANIMALE.: NET SALES ($MILLION)
FIGURE 49.HUVEPHARMA EOOD.: NET SALES ($MILLION)
FIGURE 50.MERCK & CO., INC.: NET SALES ($MILLION)
FIGURE 51.VENKATESHWARA HATCHERIES PRIVATE LIMITED.: NET SALES ($MILLION)
FIGURE 52.DOSH PHARMACEUTICALS.: NET SALES ($MILLION)
FIGURE 53.VETOQUINOL SA.: NET SALES ($MILLION)
FIGURE 54.VIRBAC SA.: NET SALES ($MILLION)
FIGURE 55.ZOETIS INC.: NET SALES ($MILLION)
FIGURE 56.BAYER AG.: NET SALES ($MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings